• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • Our Pillars
        • ARIKAYCE®
        • Brensocatib
        • TPIP
        • Early-Stage Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Feb 11, 2008
    Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
  • Feb 5, 2008
    Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
  • Feb 5, 2008
    Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
  • Jan 28, 2008
    Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
  • Jan 22, 2008
    Insmed Completes External Assessment of Myotonic Muscular Dystrophy Market
  • Dec 18, 2007
    Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
  • Dec 12, 2007
    Insmed Awarded $2.1 Million by Muscular Dystrophy Association
  • Dec 6, 2007
    Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
  • Dec 6, 2007
    Insmed Appoints Dennis M. Lanfear to Board Of Directors
  • Dec 3, 2007
    Insmed Retains FD and Gibraltar Associates for Investor Relations and Corporate Communications
  • Nov 13, 2007
    Insmed Advances Follow on Biologics Initiative
  • Nov 8, 2007
    Insmed Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2007
  • Nov 5, 2007
    Insmed Announces Initiation of Phase II Clinical Trial with IPLEX(TM) in Myotonic Muscular Dystrophy
  • Oct 24, 2007
    Insmed Announces Third Quarter Earnings Release Date and Conference Call
  • Oct 23, 2007
    Insmed to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
  • Oct 3, 2007
    Insmed to Present at the 2007 BIO Investor Forum on Wednesday, October 10, 2007
  • Aug 2, 2007
    Insmed Reports Financial Results for Second Quarter and First Half of 2007
  • Jul 25, 2007
    Insmed Announces Second Quarter and First Half Earnings Release Date and Conference Call
  • Jul 9, 2007
    Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
  • Jun 26, 2007
    Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
  • Jun 25, 2007
    Experienced Biopharmaceutical Executive Steve Glover Joins Insmed; Will Lead Development of Follow-on Biologics
  • Jun 19, 2007
    Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
  • May 10, 2007
    Insmed Incorporated Reports Financial Results for First Quarter Ended March 31, 2007
  • May 7, 2007
    Insmed Announces First Quarter Earnings Release Date and Conference Call
  • May 4, 2007
    Insmed Raises Approximately $18.2 Million in Registered Direct Offering
  • May 3, 2007
    Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
  • May 2, 2007
    Insmed CEO Geoffrey Allan Testifies at Energy and Commerce Committee Hearing
  • Apr 30, 2007
    Insmed Releases Positive Results from IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
  • Apr 25, 2007
    Insmed Inc. Releases Investor Fact Sheet with Updates on Drug Development Progress
  • Mar 26, 2007
    Insmed CEO Geoffrey Allan Testifies at Congressional Hearing
  • Mar 16, 2007
    Insmed Announces Additional Information In Compliance With NASDAQ Rules
  • Mar 15, 2007
    Insmed Inc. Reports Financial Results for Fourth Quarter and Twelve Months
  • Mar 10, 2007
    Update: Insmed to Hold 2006 Q4 and Year End Earnings Results
  • Mar 9, 2007
    Insmed to Hold 2006 Q4 and Year End Earnings Results
  • Mar 7, 2007
    Insmed Announces Restructure, Settlement Ending IPLEX(TM) Patent Dispute
  • Mar 6, 2007
    Insmed to Discuss Litigation Settlement with Tercica
  • Jan 10, 2007
    Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
  • Dec 13, 2006
    Insmed Announces Positive IPLEX(TM) Product Information At GRS-IGF Society Meeting in Kobe, Japan
  • Dec 7, 2006
    Insmed to Host Litigation Update Conference Call
  • Dec 6, 2006
    Insmed Patent Litigation Verdict Announced
  • Nov 21, 2006
    Insmed to Present at Upcoming Investor Conference in NYC
  • Nov 3, 2006
    Insmed Incorporated Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2006
  • Oct 31, 2006
    Insmed Inc. to Announce 2006 Third Quarter Financial Results
  • Oct 31, 2006
    Jody LoMenzo Named Director, Investor Relations and Corporate Communications
  • Oct 30, 2006
    Insmed to Present at Upcoming Conferences
  • Oct 25, 2006
    Former Amgen Manufacturing Executive Joins Insmed
  • Oct 24, 2006
    Insmed Announces Addition of Top 25 Patent Lawyer to Litigation Team
  • Oct 17, 2006
    Insmed to Present at the BIO Investor Forum Meeting
  • Oct 16, 2006
    Insmed Sues Tercica for False Advertising
  • Oct 5, 2006
    Insmed Provides Update Concerning Virginia Unfair Competition Litigation
Show 5102550100 per page
  • «
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy